X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the license agreement, Tenax will be developing and commercializing the TNX-103 (levosimendan) for the treatment of pulmonary hypertension with heart failure with preserved ejection fraction.
Lead Product(s): Levosimendan
Therapeutic Area: Cardiology/Vascular Diseases Product Name: TNX-103
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Orion Corporation
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement February 20, 2024
Details:
The company intends to use the net proceeds for the clinical development of TNX-103 (levosimendan) for the treatment of pulmonary hypertension and heart failure with preserved ejection fraction.
Lead Product(s): Levosimendan
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: TNX-103
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Roth Capital Partners
Deal Size: $9.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 08, 2024
Details:
TNX-103 (levosimendan) is a potassium ATP channel activator and calcium sensitizer that affects the heart & vascular system. It is being evaluated in phase 3 trials for the treatment of pulmonary hypertension in heart failure with preserved ejection fraction (PH-HFpEF).
Lead Product(s): Levosimendan
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: TNX-103
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 07, 2024
Details:
TNX-103 (levosimendan), is an oral, small molecule, unique potassium ATP channel activator and calcium sensitizer, being developed for Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction. There are currently no FDA approved treatments for PH-HFpEF.
Lead Product(s): Levosimendan
Therapeutic Area: Cardiology/Vascular Diseases Product Name: TNX-103
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 13, 2023
Details:
TNX-103 (levosimendan), is an oral, small molecule, unique potassium ATP channel activator and calcium sensitizer, being developed for Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction. There are currently no FDA approved treatments for PH-HFpEF.
Lead Product(s): Levosimendan
Therapeutic Area: Cardiology/Vascular Diseases Product Name: TNX-103
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 31, 2023
Details:
TNX-101 (levosimendan) is a unique potassium ATP channel activator and calcium sensitizer that affects the heart and vascular system through multiple mechanisms of action.
Lead Product(s): Levosimendan
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: TNX-101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 22, 2023
Details:
The Company intends to use the net proceeds to progress the clinical development of TNX-201 (imatinib) for the treatment of PAH and levosimendan for the treatment of PH-HFpEF, toward regulatory approval for the treatment of these and potentially other indications.
Lead Product(s): Imatinib Mesylate
Therapeutic Area: Cardiology/Vascular Diseases Product Name: TNX-201
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Roth Capital Partners
Deal Size: $15.6 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 03, 2023
Details:
TNX-101 (levosimendan) is a unique potassium ATP channel activator and calcium sensitizer that affects the heart and vascular system through multiple mechanisms of action.
Lead Product(s): Levosimendan
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: TNX-101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 01, 2023
Details:
Levosimendan (TNX-102 and TNX-103) is a unique potassium ATP channel activator and calcium sensitizer that affects the heart and vascular system through multiple mechanisms of action.
Lead Product(s): Levosimendan
Therapeutic Area: Cardiology/Vascular Diseases Product Name: TNX-102
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Orion Corporation
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 10, 2022
Details:
TNX-201 (imatinib), a novel, oral, modified release formulation, a kinase inhibitor that has received FDA’s orphan designation for the treatment of pulmonary arterial hypertension (PAH).
Lead Product(s): Imatinib Mesylate
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: TNX-201
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 25, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
